Long-term Follow-up Protocol for Subjects Treated with Adicet Bio Allogeneic Gamma Delta (γδ) T Cell Investigational Products
MD Anderson Study Status
The purpose of this study is to assess long-term side effects from subjects who receive an Adicet Bio gamma delta T cell product. Subjects who previously took part in an Adicet Bio study and received gamma delta T cell therapy will take part in this long-term follow-up study. Subjects will join this study once they complete the parent interventional study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study. For a period of 15 years from the last administration of Adicet Bio allogeneic gamma delta T cell product, subjects will be assessed for long-term safety and survival through collection of data that include safety, efficacy , pharmacokinetics and immunogenicity.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Lymphoma, Follicular, Lymphoma, Mantle-Cell, Marginal Zone Lymphoma, Lymphoma, Burkitt, Mediastinal Lymphoma, Diffuse Large B Cell Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.